Physician profile
Harrison Hasanuddin
NPI 1790165785
$14,600.37
in general payments reported to CMS, 2019-2025
45 companies · $993 in 2025
The $993 reported for 2025 was more than what a typical Sleep Medicine (Family Medicine) provider received nationally (typical 2025 total: $557).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,983 · 2020: $585 · 2021: $436 · 2022: $5,607 · 2023: $2,556 · 2024: $1,439 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,988.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $3,930.00 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $1,106.54 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Amgen INC. | $1,090.25 | 2019-2024 | Krystexxa, Otezla, Repatha |
| Gilead Sciences, INC. | $910.76 | 2019-2020 | |
| Abbvie INC. | $892.37 | 2019-2024 | |
| Lilly USA, LLC | $835.51 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $708.44 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novo Nordisk INC | $651.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $524.57 | 2022-2025 | |
| Glaxosmithkline, LLC. | $373.90 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $287.70 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $271.79 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $264.51 | 2023-2025 | Gemtesa |
| Shire North American Group INC | $259.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.55 | 2020-2025 | Jardiance |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harrison Hasanuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.